Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study.

Shiraki A, Hara C, Akasaka H, Nakagami H, Sugimoto K, Yasunobe Y, Minami T, Fujimoto T, Yamamoto K, Asano K, Kanou M, Yamana K, Imai SI, Rakugi H, Nishida K

Geriatrics & gerontology international1 May 2026Cited by 1 (Europe PMC)

PMID42082179DOI10.1111/ggi.70516PepBankPUB-42082179

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In older men with diabetes, outer temporal retinal thickness change was higher with NMN than placebo at 24 weeks.
In plain wordsIn older men with diabetes, outer temporal retinal thickness change was higher with NMN than placebo after 24 weeks.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseOuter temporal retinal thickness change
Study
n = 14
Comparator
Placebo
Outcome group
Vision and retina · Eye
Studied dose
250 mg/day · oral · 24 weeksAs given in this study (human).
Measurements
Retinal thickness change
1.14 μm
NMN
Retinal thickness change
−2.77 μm
Placebo
p value
0.006
Between groups
Source sentences
Summary
In the temporal subretinal field of the outer circle, the retinal thickness change from baseline to 24 weeks differed significantly between the NMN and placebo groups (+1.14 ± 2.85 μm and -2.77 ± 3.30 μm, respectively; p = 0.006).
3 context sentences(design, population, supporting numbers)
Summary · context
Before and 24 weeks after the study initiated, 240 × 240 mm macular cube scan optical coherence tomography images were obtained from male patients with type 2 diabetes aged ≥ 65 years with physical frailty; changes in the automatically measured mean retinal thickness within the 9 ETDRS grid regions…
Summary · context
Participants were randomly assigned to receive 250 mg/day NMN or placebo orally for 24 weeks.
Summary · context
Each group included 14 eyes of 7 patients; 8 eyes had ocular disease.
Report a problemFND-4208217902
02HumanRandomized controlled trialSafety outcome
In older men with diabetes receiving NMN, no systemic adverse events were observed.
In plain wordsIn older men with diabetes receiving NMN, no systemic adverse events occurred.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableSystemic adverse events
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
250 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Systematic and ophthalmic adverse events were not observed in the NMN group.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly assigned to receive 250 mg/day NMN or placebo orally for 24 weeks.
Summary · context
Each group included 14 eyes of 7 patients; 8 eyes had ocular disease.
Summary · context
Before and 24 weeks after the study initiated, 240 × 240 mm macular cube scan optical coherence tomography images were obtained from male patients with type 2 diabetes aged ≥ 65 years with physical frailty; changes in the automatically measured mean retinal thickness within the 9 ETDRS grid regions…
Report a problemFND-4208217904
03HumanRandomized controlled trialSafety outcome
In older men with diabetes receiving NMN, no ophthalmic adverse events were observed.
In plain wordsIn older men with diabetes receiving NMN, no eye adverse events occurred.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicableOphthalmic adverse events
Study
n = 7
Outcome group
Adverse events · Eye
Studied dose
250 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Systematic and ophthalmic adverse events were not observed in the NMN group.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly assigned to receive 250 mg/day NMN or placebo orally for 24 weeks.
Summary · context
Each group included 14 eyes of 7 patients; 8 eyes had ocular disease.
Summary · context
Before and 24 weeks after the study initiated, 240 × 240 mm macular cube scan optical coherence tomography images were obtained from male patients with type 2 diabetes aged ≥ 65 years with physical frailty; changes in the automatically measured mean retinal thickness within the 9 ETDRS grid regions…
Report a problemFND-4208217905
04HumanRandomized controlled trialEfficacy outcome
In participants without ocular disease, NMN showed a nonsignificant trend toward less temporal retinal thinning than placebo (p = 0.07).
In plain wordsIn participants without eye disease, NMN showed a nonsignificant trend toward less temporal retinal thinning than placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeTemporal retinal thickness without ocular disease
Study
n: not reported in source
Comparator
Placebo
Outcome group
Vision and retina · Eye
Studied dose
250 mg/day · oral · 24 weeksAs given in this study (human).
Measurements
Retinal thickness change
0.75 μm
NMN without ocular disease
Retinal thickness change
−2.45 μm
Placebo without ocular disease
p value
0.07
Without ocular disease
Source sentences
Summary
Among patients without ocular disease, the NMN group demonstrated a trend toward suppressed reduction in retinal thickness in the temporal region (+0.75 ± 3.20 μm and -2.45 ± 3.33 μm in the NMN and placebo groups, respectively; p = 0.07).
2 context sentences(design, population, supporting numbers)
Summary · context
Before and 24 weeks after the study initiated, 240 × 240 mm macular cube scan optical coherence tomography images were obtained from male patients with type 2 diabetes aged ≥ 65 years with physical frailty; changes in the automatically measured mean retinal thickness within the 9 ETDRS grid regions…
Summary · context
Participants were randomly assigned to receive 250 mg/day NMN or placebo orally for 24 weeks.
Report a problemFND-4208217903

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

05HumanNot a test of NMN (nicotinamide mononucleotide) aloneRandomized controlled trialEfficacy outcome
In older men with diabetes, visual acuity did not change significantly in either the NMN or placebo group.
In plain wordsIn older men with diabetes, vision did not change significantly in either the NMN or placebo group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeBest-corrected visual acuity
Study
n = 14
Outcome group
Vision and retina · Eye
Source sentences
Summary
Best-corrected visual acuity did not change significantly between baseline and 24 weeks for both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Before and 24 weeks after the study initiated, 240 × 240 mm macular cube scan optical coherence tomography images were obtained from male patients with type 2 diabetes aged ≥ 65 years with physical frailty; changes in the automatically measured mean retinal thickness within the 9 ETDRS grid regions…
Summary · context
Participants were randomly assigned to receive 250 mg/day NMN or placebo orally for 24 weeks.
Summary · context
Each group included 14 eyes of 7 patients; 8 eyes had ocular disease.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Report a problemFND-4208217901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.